Neuroleptic malignant syndrome (NMS): a medical emergency

Of all the side effects of antipsychotic medication, neuroleptic malignant syndrome — usually shortened to NMS — is the one every patient, family member, and clinician should know how to recognise. It is rare. It is dramatic. It is potentially fatal. And early recognition is the single most important factor in survival.

What NMS is

NMS is an idiosyncratic reaction to dopamine-blocking medications. The leading mechanistic theory is sudden, severe disruption of dopamine signalling in the brain — particularly in the hypothalamus (which controls temperature) and the basal ganglia (which controls movement). The result is a syndrome that affects multiple body systems at once.

The classic four features

The diagnosis traditionally rests on four findings together:

1. Hyperthermia — fever, often 38°C (100.4°F) or higher, and sometimes much higher
2. Muscular rigidity — often described as "lead pipe" stiffness throughout the body
3. Altered mental state — confusion, delirium, stupor, or coma
4. Autonomic instability — fluctuating blood pressure, fast or irregular heart rate, sweating, salivation

Laboratory findings often include a markedly elevated creatine kinase (CK) from muscle breakdown, raised white cell count, and abnormal electrolytes.

How rare is it?

Reported rates have decreased over the decades as awareness has improved. Modern estimates suggest NMS occurs in roughly 0.01% to 0.02% of patients exposed to antipsychotics — meaning one in five thousand to ten thousand. Mortality, when it occurs, is around 5–20% — much lower than it once was, but still significant.

Which medications cause it

NMS can occur with virtually any dopamine-blocking medication, including:

• All antipsychotics — typical and atypical
• Antiemetics that block dopamine (metoclopramide, prochlorperazine)
• Withdrawal of dopaminergic medications in Parkinson's disease (a related "NMS-like" syndrome)

Higher-potency typical antipsychotics (haloperidol, fluphenazine) historically had the highest reported rates. Atypical antipsychotics, while lower-risk, are not exempt — clozapine, olanzapine, risperidone, and others have all been implicated. Long-acting injections can produce delayed presentations.

Risk factors

• Recent dose increase or starting a new antipsychotic
• High-potency typical antipsychotic
• Use of multiple antipsychotics together
• Rapid IV administration
• Dehydration
• Hot environments
• Severe agitation
• Previous episode of NMS
• Withdrawal from anti-Parkinson medications

Early warning signs

NMS doesn't always announce itself with the full picture at once. Earlier signs that should raise concern include:

• Unexplained fever in someone on antipsychotics
• New muscle stiffness or tremor that is more severe than ordinary EPS
• Unusual confusion or drowsiness
• Profuse sweating
• Rapid heart rate without obvious cause
• Difficulty swallowing or speaking due to rigidity
• Drooling

Many cases progress over 1–3 days. Some progress over hours. Catching it in the early hours improves outcomes significantly.

How it's diagnosed

There is no single test. Diagnosis is clinical, based on the combination of features in someone exposed to a relevant medication. Other conditions can mimic NMS — serotonin syndrome (from antidepressants), malignant hyperthermia (a similar reaction to anaesthetics), severe infections, heat stroke, severe extrapyramidal reactions — and distinguishing them is part of the emergency workup.

Investigations typically include CK level, white cell count, kidney function, electrolytes, urinalysis (for myoglobin from muscle breakdown), and often a CT or lumbar puncture to rule out infection.

How it's treated

NMS treatment is intensive and almost always inpatient. The core elements:

1. Immediate discontinuation of the offending medication
2. Aggressive cooling for hyperthermia
3. Intravenous fluids to prevent kidney injury from rhabdomyolysis (muscle breakdown)
4. Cardiovascular support for blood pressure and heart rate instability
5. Specific medications in moderate-to-severe cases:
   • Dantrolene — a muscle relaxant that addresses rigidity
   • Bromocriptine — a dopamine agonist that addresses the underlying dopamine blockade
   • Benzodiazepines — for agitation and to support muscle relaxation
6. ECT — sometimes considered in severe or refractory cases

Most episodes resolve over 7–14 days with appropriate care.

Recovery and what comes next

Most people who survive NMS recover fully. The biggest decision afterwards is whether and how to restart an antipsychotic — particularly important for someone whose underlying psychiatric condition still needs treatment. Restarting is generally possible but done with great care:

• Wait at least 2 weeks (usually longer) after full resolution
• Use a different drug class if possible — typically a lower-potency atypical antipsychotic such as quetiapine or clozapine
• Start at very low doses with slow titration
• Monitor closely for early NMS signs

Recurrence rates with cautious rechallenge are roughly 30%, but most recurrences are milder and recognised earlier.

What patients and families can do

The most important thing is awareness. Knowing what NMS looks like, knowing it's a medical emergency, and being willing to bring someone to A&E even if you're not sure — these are the things that save lives. NMS is a textbook example of a condition where the layperson's recognition of "something is very wrong, this isn't ordinary" is more important than any test.

This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.